Sign in
Not yet taking people in GermanyPhase 2

Testing immunotherapy, with or without other drugs, in lung cancer that cannot be removed

Tests immunotherapy with or without other drugs in adults with inoperable lung cancer.

Key facts

Who runs it
AstraZeneca AB
Where
Frankfurt Am Main, Freiburg im Breisgau, and Homburg, GermanySee the 3 sitesAlso in 1 other country, 4 sites
Registry title
A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer
Status
Not yet recruiting
Phase
Phase 2
People taking part
11 people, planned
Starts
29 Jan 2027
Expected to end
27 Jul 2029
Type of study
Interventional
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage III non-small cell lung cancer that cannot be removed by surgery and who plan to have chemotherapy together with radiation.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Unresectable stage III non-small cell lung cancer (squamous or non-squamous), able to have platinum-based chemotherapy with radiation to a total of 60 Gy in 30 fractions. At least one tumour measurable on CT or MRI.
Earlier treatment
No earlier systemic or radiation treatment for this lung cancer, and no earlier radiation that included lung tissue. No earlier anti-PD-1, anti-PD-L1 or anti-TIGIT treatment, or other treatment aimed at immune regulatory receptors.
Biomarker or test result
No sensitizing EGFR mutation and no ALK rearrangement. No known ROS1 or RET rearrangement. Tumour PD-L1 result must be known, with tumour tissue available to confirm it.

Main reasons for not taking part

  • Small cell or neuroendocrine parts in the tumour, or a sarcomatoid or other rare type
  • Fluid around the lung or heart that contains cancer cells
  • Lung scarring or inflammation, such as pulmonary fibrosis, ILD or pneumonitis that needed steroids
  • History of organ transplant or allogeneic stem cell transplant
  • Autoimmune or inflammatory disease needing long-term treatment with medicines that act on the whole body

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Histologically or cytologically documented squamous or non-squamous NSCLC
  • Unresectable stage III NSCLC eligible for concurrent chemoradiation. (Stage should be determined based on IASLC v9.0 Staging Guidelines; resectability should be determined by a multidisciplinary evaluation.)
  • Documented absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) rearrangements
  • No known ROS1 or RET rearrangements detected as per local standard practice
  • Eligible for definitive, platinum-based cCRT to a total radiation dose of 60 Gy in 30 fractions using photons
  • ECOG performance status of 0 or 1
  • and 10. Known tumor PD-L1 "XXX" expression using documented local results with confirmed availablity of tumor tissue sample to confirm PD-L1 expression results
  • At least one lesion that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT (preferred) or MRI, and is suitable for accurate repeated measurements
  • Adequate organ and bone marrow function

Who cannot take part

  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years prior to treatment assigment and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease
  • Active or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment
  • Any prior or current systemic or radiation therapy received for NSCLC, or prior radiation therapy for any malignancy that included any lung tissue in the prior radiation fields
  • Prior exposure to an anti-PD-1, anti-PD-L1, or anti-TIGIT therapy, or any other anticancer therapy targeting immune regulatory receptors or mechanisms
  • Malignant pleural or pericardial effusion. Effusions must be assessed via thoracentesis or pericardiocentesis
  • History of idiopathic pulmonary fibrosis, ILD, non-infectious/radiation ILD/pneumonitis that required steroids or any active signs of these conditions that cannot be ruled out by imaging at screening. Additional exclusions include organizing pneumonia or drug-induced pneumonitis/ILD
  • History of organ transplant or allogeneic stem cell transplant
  • Presence of small cell and/or neuroendocrine histology components; sarcomatoid variant; and/or other rare subtypes
  • Tumor invasion of the great vessels (aorta, superior/inferior vena cava, and/or intrapericardial vessels)

Where in Germany

Also in 1 other country, 4 sites

  • Goethe University FrankfurtFrankfurt Am Main, GermanyNot yet recruiting
  • Medical Center- University of FreiburgFreiburg im Breisgau, GermanyNot yet recruiting
  • Universitaet Des SaarlandesHomburg, GermanyNot yet recruiting

About the trial

What the trial wants to find out

To assess the safety and tolerability of immunotherapy with or without other anticancer drugs in participants with unresectable Stage III NSCLC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
Plain-language title
Testing immunotherapy, with or without other drugs, in lung cancer that cannot be removedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 August 2026